NCT01724801

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

Phase III Study of Icotinib Treat the Patient With Brain Metastasis EGFR-mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 176 (actual)
• Sponsor: Guangdong Association of Clinical Trials · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

EGFR-TKI is good for the patients with EGFR-mutant non-small cell lung cancer.We design this clinical trail to confirm if the efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor(EGFR-TKI )(ICOTINIB) is better than whole brain irradiation for the patient with EGFR-mutant non-small cell lung cancer.

Detailed description

no available

Conditions

• Brain Metastasis
• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
RADIATION	whole brain radiation(WBI)	WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles
DRUG	Icotinib	administered orally at a dose of 125 mg 3 times daily

Timeline

• Start date: 2012-10-14
• Primary completion: 2015-06-30
• Completion: 2016-09-14
• First posted: 2012-11-12
• Last updated: 2017-03-01

Locations

2 sites across 1 country: China